Hurdle cleared:
"Additional experiments will now be performed on SARS-CoV-2 infected human lung cell lines."
Now the sell through? This is extremely promising news - the company is looking more and more likely to be sitting on a very safe and very effective anti-viral to treat CoV infections, including COVID-19, just at a time that the world is waking up the reality that vaccines alone won't be enough. This ought to be shouted from the rooftops, so let's see how management does with its (apparently) refreshed approach to comms...
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity, page-10
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.010(5.41%) |
Mkt cap ! $73.24M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 24.0¢ | 19.5¢ | $1.601M | 7.439M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 60000 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 123426 | 6 |
View Market Depth
| Last trade - 10.42am 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
19.0¢ |
Change
0.010 ( 4.17 %) |
||||
| Open | High | Low | Volume | ||
| 23.5¢ | 24.0¢ | 19.0¢ | 5710336 | ||
| Last updated 10.57am 17/05/2024 ? | |||||
| PAA (ASX) Chart |